Status:
RECRUITING
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e...
Detailed Description
This is a type one hybrid effectiveness-implementation study consisting of three aims. Aim one (Months 1-15) focuses on MSS enhancement using stakeholder collaboration. Aim two (Months 16-60) involves...
Eligibility Criteria
Inclusion
- Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
- Three months to five years post-surgery
- No current evidence of cancer
- Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months)
- ≥ 18 years old
- Internet access
- Able to speak/read English
- Able to provide informed consent
Exclusion
- Children
Key Trial Info
Start Date :
March 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
385 Patients enrolled
Trial Details
Trial ID
NCT05373823
Start Date
March 6 2023
End Date
March 31 2027
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901